RUNX3 and pancreatic neoplasm: If the combination of RUNX3 and SMAD4 status could predict the behavior of PDAC, analyzing RUNX3 and SMAD4 protein expression status by immunohistochemistry in resected or biopsied PDAC tissues would greatly benefit pancreatic cancer patients by helping to guide treatment plans.